📅 PUBMED DAILY TRIAGE — 2026-03-29

Window: 2026-03-28T09:00:00Z → 2026-03-29T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: 13 (12 kept + 1 excluded by type) High priority: 0 | Standard: 9 | Low/archive: 2 | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY

No articles met HIGH priority threshold (triage_score ≥ 8 or EARLY_CANCER_DETECTION/NOVEL_TREATMENT with score ≥ 8) this run.

Note: Two articles carry EARLY_CANCER_DETECTION flag at score 7 (TR-2026-03-29-001, -002) — one step below HIGH threshold. Recommend Phase 2 review for validation potential.

🟢⚪ STANDARD

TR-2026-03-29-001 · Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma · 7/10 · 🔴 Discovery-phase serum proteomics 3-protein panel (ITIH3/F13A1/FTL, AUC 0.98) for resectable PDAC — high unmet need, needs external validation.

TR-2026-03-29-002 · Clinical Utility of ctDNA Analysis for Assessing Completeness of Melanoma Resection (Systematic Review, n=1,077) · 7/10 · 🔴 Systematic review confirming postoperative ctDNA clearance as consistent MRD/relapse predictor in melanoma across 14 studies.

TR-2026-03-29-009 · Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists vs Non-GLP-1: FDA Data, 70K+ Subjects · 7/10 · 🟢 Large-scale FDA comparative analysis: tirzepatide has greatest weight loss + lowest mortality RR; WM single-agonist GLP-1s carry higher neoplasm signal (5.4% vs 0.7%).

TR-2026-03-29-005 · Predicting Long-Term Depression Progression in Parkinson's Disease: ML Survival Analysis (PPMI, n=496) · 6/10 · 🟢 Explainable RSF model (C-index 0.744) stratifies PD depression risk using routine variables; PPMI-validated; AI/ML diagnostics category.

TR-2026-03-29-008 · Phase 1 PROGEM Trial: Proglumide + Chemotherapy in Metastatic Pancreatic Cancer — TME Effects · 6/10 · 🟠 Phase 1 human trial showing CCK-antagonist proglumide remodels TME (↑CD8+, ↓M2-TAMs) in metastatic PDAC; novel mechanism, well-tolerated.

TR-2026-03-29-011 · GLP-1 RA Initiation and TSH Monitoring Gaps in Levothyroxine Users: Medicare Trial Emulation, n=5,370 · 6/10 · 🟢 Actionable real-world quality gap: 83% TSH testing rate unchanged vs SGLT-2i despite GLP-1-induced weight loss requiring levothyroxine re-titration.

TR-2026-03-29-006 · Anoikis-Related Gene Signature for Prognosis and Immunotherapy Response in Lung Squamous Cell Carcinoma · 5/10 · ⚪ Bioinformatic prognostic nomogram (S100A7/S100A8/SPP1) for LUSC; immune-suppression profiling; needs prospective validation.

TR-2026-03-29-007 · Immune, Molecular and Genetic Profiles of Gastric Signet Ring Cell Carcinoma: Review · 5/10 · 🟠 Mechanistic review: GSRCC immunotherapy resistance driven by CXCL13-depleted CD8-Tex cells; CLDN18.2 (zolbetuximab) validated target.

TR-2026-03-29-010 · Empagliflozin Reduces Epicardial Adipose Tissue and Improves Diastolic Function in T2DM: Prospective Study (n=75) · 5/10 · ⚪ Prospective EAT thinning + diastolic improvement with empagliflozin; single-arm, hypothesis-generating.

💡 UNSOLICITED FINDS

TR-2026-03-29-013 (PMID 41902519) · Local Brain Hypercorrelations Positively Associate with PTSD Severity (resting-state fMRI, n=36) · 4/10 fMRI neuroimaging biomarker in veterans; frontal/limbic hypercorrelation as PTSD severity marker. Small n=36; captured via AI/imaging topic overlap.

🗃️ LOW / ARCHIVE

TR-2026-03-29-004 (PMID 41902444) · TIVAD Infections in Oncology vs Hematology: Retrospective Single-Center · 3/10 · Hematology patients have 2.7× higher TIVAD infection rate; single-center, limited generalizability.

TR-2026-03-29-012 (PMID 41901737) · NGS-Based Profiling in Early-Stage PDAC [title-only] · 3/10 · Title-only record; score capped; Phase 2 should retrieve full abstract.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 3
• Treatment Innovation: 3
• Diagnostics: 3
• Genomics/Precision Medicine: 2
• Drug Development: 2
• Public Health: 2
• Other: 1

By evidence maturity:

• Exploratory: 7
• Validated: 4
• Potentially Practice-Changing: 0

By watchlist topic:

• Cardiovascular-metabolic (GLP-1/SGLT2): 3
• Early cancer detection (ctDNA/liquid biopsy): 2
• Novel therapeutics (immunotherapy/targeted): 3
• Hematologic malignancies: 2
• AI/ML diagnostics: 3
• Precision oncology/genomic medicine: 2
• Sentinel/unsolicited: 1

By source type: peer_reviewed 12 | preprint 0

By pipeline priority: STANDARD 9 | LOW 2

🔧 RUN NOTES

• Window: 24-hour incremental (2026-03-28T09:00Z → 2026-03-29T09:00Z); no expansion triggered (12 relevant records found, ≥ 5 threshold)
• Exclusions applied: PMID 41902464 (Editorial/Comment, SGLT2/heart failure); PMID 41902340 (Letter, tirzepatide/Ramadan) — excluded per default exclusion rules; no exceptions invoked
• Aging/longevity topic: 286 results; no net-new distinct articles kept after cross-topic deduplication
• Rare disease topic: 4 results; none met abstract-quality threshold on review
• Title-only record (TR-012): Score capped at 3 per schema; full abstract retrieval recommended in Phase 2
• Alert threshold: No articles reached triage_score ≥ 8 this run; no HIGH priority alerts emitted per Output C rules
• Note on borderline articles: TR-001 (PDAC proteomics, score 7, 🔴) and TR-002 (melanoma ctDNA SR, score 7, 🔴) carry EARLY_CANCER_DETECTION flags but did not cross HIGH threshold; both are strong STANDARD candidates for Phase 2 deep-dive
• GLP-1 safety signal (TR-009): WM GLP-1 RA postmarketing neoplasm rate (5.4%) vs GLP-1/GIP (0.7%) is a notable pharmacovigilance finding worth monitoring for pipeline escalation
• Deduplication: Zero PMIDs overlap with prior 76-fingerprint set from state.json